Phase 2CompletedINTERVENTIONAL
Tirzepatide for Obesity and Meth Use Disorder
ClinicalTrials.gov · NCT06745128 · Registry updated: 2026-09-28
- Condition / research focus
- Obesity; Methamphetamine Use Disorder
- Sponsor
- University of Texas Southwestern Medical Center
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2025-02-03. Completion: 2026-02-12 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Tirzepatide (drug) — also listed as: ZEPBOUND, MOUNJARO
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- UT Southwestern Medical Center
Dallas, Texas, United States
Site recruitment: Not reported